The Partners Healthcare Systems/Harvard Medical School/Boston Medical Center AIDS Clinical Trials Unit, previously known as the Harvard Medical School/Boston Medical Center (HMS/BMC) AIDS CTU, comprises a consortium of clinical research sites (CRS) affiliated with the AIDS Clinical Trials Group (ACTG) network leadership group. The CRSs are located at Massachusetts General Hospital (MGH), Brigham and Women's Hospital (BWH), Beth Israel-Deaconess Medical Center (BIDMC), and Boston Medical Center (BMC), with an administrative component located at MGH. Throughout its 19-year history, investigators of the HMS/BMC AIDS CTU have made major contributions to therapeutic research in AIDS and have played a critical role in the scientific leadership of the ACTG: pivotal studies demonstrating clinical efficacy of combination antiretroviral therapy, protease inhibitor therapy, and combination therapy of HCV in co-infected persons all have been led by HMS/BMC AIDS CTU investigators. We propose a comprehensive, integrated clinical and translational research program that addresses five of the six priority areas described in the Network Leadership Group RFA (AI-05-001), including: 1) translational research/drug development;2) optimization of clinical management, including co-morbidities;3) vaccine development (therapeutic vaccines);4) prevention of mother-to-child transmission (in collaboration with the Boston IMPAACT Clinical Trials Unit);and 5) prevention of HIV-1 infection. In addition, the Partners/Harvard/BMC AIDS CTU has formed mentoring partnerships with the Botswana CTU in Gaborone and the Chinese Academy of Medical Sciences/Peking Union Medical College CTU in Beijing through which investigators and research staff of the Partners/Harvard/BMC AIDS CTU provide training and guidance in the conduct of ACTG trials. Recruitment of women and subjects from traditionally underrepresented minority groups is a top priority of the Partners/Harvard/BMC AIDS CTU. This goal is aided by location of two of our CRSs (BWH and BMC in predominantly minority neighborhoods, and outreach efforts coordinated with our Community Advisory Board. Results of the studies proposed in this application will have a profound impact on public health by improving clinical care, preventing or delaying HIV disease progression, and reducing or eliminating the morbidity and mortality associated with HIV-1 infection and its associated complications. ADMINISTRATIVE COMPONENT

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1AI069472-07
Application #
8402562
Study Section
Special Emphasis Panel (ZAI1-TP-A (M2))
Program Officer
Germuga, Donna E
Project Start
2007-02-01
Project End
2014-11-30
Budget Start
2012-12-01
Budget End
2014-11-30
Support Year
7
Fiscal Year
2013
Total Cost
$2,290,646
Indirect Cost
$155,537
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Lennox, Jeffrey L; Landovitz, Raphael J; Ribaudo, Heather J et al. (2014) Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med 161:461-71
Leger, Paul D; Johnson, Daniel H; Robbins, Gregory K et al. (2014) Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384. J Neurovirol 20:304-8
Zheng, Yu; Hughes, Michael D; Lockman, Shahin et al. (2014) Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens. Clin Infect Dis 59:888-96
Haas, David W; Kwara, Awewura; Richardson, Danielle M et al. (2014) Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes. J Antimicrob Chemother 69:2175-82
Johnson, Daniel H; Venuto, Charles; Ritchie, Marylyn D et al. (2014) Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 24:195-203
Touzard Romo, F; Smeaton, L M; Campbell, T B et al. (2014) Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175). HIV Clin Trials 15:246-60
Jacobson, Jeffrey M; Wang, Hongying; Bordi, Rebeka et al. (2014) A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy. J Acquir Immune Defic Syndr 66:399-406
Safren, Steven A; Biello, Katie B; Smeaton, Laura et al. (2014) Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175/PEARLS trial. PLoS One 9:e104178
Thio, Chloe L; Smeaton, Laura; Saulynas, Melissa et al. (2013) Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort. AIDS 27:191-201
Sax, Paul E (2013) Editorial commentary: can we break the habit of routine CD4 monitoring in HIV care? Clin Infect Dis 56:1344-6

Showing the most recent 10 out of 14 publications